LXRX Lexicon Pharmaceuticals, Inc.
$1.38▼ -6.76%
Healthcare
Other
Volume 1.20M
Avg Volume (10D) 1.80M
Key Metrics & Fundamentals
Market Cap
$614.04M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.10 - 2.68
% vs 50 MA
-22.27%
% vs 200 MA
-21.44%
RSI-14
32.3
MACD Histogram
+0.0100
Beta (1Y vs SPY)
1.45
Free Cash Flow
-$9.19M
Gross Rev
$692,000
Gross Profit
$653,000
EBITDA
-$24.72M
COGS
$39,000
Operating Exp
$27.19M
Operating Income
-$26.54M
EBIT
-$26.54M
Pretax Income
-$31.78M
Net Income
-$31.78M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026
GlobeNewswire · Oct 29, 2026 8:30 AM ET
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
GlobeNewswire · Oct 23, 2026 8:30 AM ET
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
GlobeNewswire · Oct 21, 2026 8:30 AM ET
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress
Simply Wall St. · Oct 2, 2026 1:10 AM ET
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
Motley Fool · Sep 28, 2026 5:25 PM ET
Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating
MT Newswires · Sep 28, 2026 2:55 PM ET
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM
Investing.com · Sep 28, 2026 12:10 PM ET
Cantor Fitzgerald Initiates Lexicon Pharmaceuticals at Overweight With $8 Price Target
MT Newswires · Sep 28, 2026 6:35 AM ET
LX-9211 Market Outlook 2026-2034 | Sales Forecast Highlights Emerging Commercial Opportunities
GlobeNewswire · Sep 25, 2026 4:21 AM ET
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
MarketBeat · Sep 20, 2026 1:01 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See LXRX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.